Lantern Pharma to Present New Preclinical Data at Three Upcoming Scientific Conferences

Rhea-AI Summary

Lantern Pharma (NASDAQ: LTRN) announced it will present new preclinical data at three scientific conferences: the Society of Neuro Oncology Annual Meeting on November 18, the San Antonio Breast Cancer Symposium on December 8, and the American Society of Hematology Annual Meeting on December 10. A key focus will be the preclinical efficacy of LP-184, a therapeutic targeting glioblastoma. Lantern Pharma leverages its proprietary RADR® platform to identify patients likely to benefit from its targeted therapies, which could significantly enhance treatment outcomes.

Positive

• Presentation of new preclinical data at three upcoming conferences.
• Focus on LP-184's efficacy in glioblastoma.
• Leverage of RADR® platform to target patient populations, potentially improving treatment outcomes.

Negative

• None.

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present new preclinical data at three upcoming scientific conferences:

• Society of Neuro Oncology Annual Meeting in Tampa, FL on November 18, from 7:30-9:30 p.m. ET.
  Poster Title: Preclinical efficacy of LP-184, a tumor site activated synthetically lethal therapeutic, in glioblastoma
  Registration: https://www.soc-neuro-onc.org/WEB/Event_Content/Annual_Meeting/Annual_Conference.aspx
  

• San Antonio Breast Cancer Symposium in San Antonio, TX on December 8, from 8:00-9:15 a.m. ET.
  Poster Title: To be announced
  Registration: https://www.sabcs.org/2022-Registration
  

• American Society of Hematology Annual Meeting in New Orleans, LA on December 10, from 6:30-8:30 p.m. ET.
  Poster Title: To be announced
  Registration: https://www.hematology.org/meetings/annual-meeting/registration-information

Further details on the new preclinical data as well as additional conference presentation details will be announced in the coming weeks.

About Lantern Pharma:
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR^® A.I. and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically-targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across nine disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes.

Please find more information at:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
Twitter: @lanternpharma

Forward-looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221025005214/en/

Nicole Leber

Investor Relations Associate

ir@lanternpharma.com

Source: Lantern Pharma Inc.

FAQ

What is Lantern Pharma's latest announcement regarding LTRN?

Lantern Pharma announced it will present new preclinical data at three upcoming scientific conferences focused on oncology, showcasing the efficacy of LP-184 in glioblastoma.

When will Lantern Pharma present preclinical data from LTRN?

The preclinical data presentations are scheduled for November 18, December 8, and December 10 at various scientific conferences.

What is the significance of LP-184 in Lantern Pharma's research?

LP-184 is being studied as a synthetically lethal therapeutic specifically targeting glioblastoma, highlighting its potential to improve patient outcomes.

How does Lantern Pharma utilize its RADR® platform?

The RADR® platform aids in discovering biomarker signatures to identify patients most likely to respond to its pipeline of genomically-targeted therapeutics.

What are the upcoming events for Lantern Pharma related to LTRN?

Upcoming events include the Society of Neuro Oncology Annual Meeting on November 18, the San Antonio Breast Cancer Symposium on December 8, and the American Society of Hematology Annual Meeting on December 10.